RainDance Technologies prides itself on its continued innovation and ability to deliver Digital Droplet-based solutions that fundamentally enhance the way researchers and scientists study cell-based and cell-free biomarkers in cancer, infectious disease and inherited disorders. We are
HemOnc experts validate unmet need and performance of new ThunderBolts™ Myeloid NGS Panel at ASH 2014 BILLERICA, Mass. — December 5, 2014 — RainDance Technologies, Inc., a genomics tools company simplifying the analysis of complex genetic diseases, today announced the formation of the
RainDance’s droplet-based platform can detect and monitor rare biomarkers for cancers, viruses, pathogens, and immune disorders with absolute precision to enable cell-free liquid biopsy research BILLERICA, Mass. -RainDance Technologies, Inc., a genomics tools company simplifying the a
RainDance Technologies® is making complex genetics simple. The company’s ultra-sensitive genomic tools enable research of novel non-invasive liquid biopsy applications that should result in more accurate, reliable, cost-effective, and early detection of cancer and other inherited and infectious diseases. Major research institutions and laboratories around the world rely on the performance of RainDance systems. Based outside Boston, Massachusetts, the company supports customers using RainDrop® Digital PCR, as well as the ThunderStorm® and ThunderBolts™ Next-Generation Sequencing Enrichment Systems through its international sales and service operations, as well as a global network of distributors and commercial service providers. Both technology platforms have been recognized by The Scientist as Top 10 Innovations with the RainDrop System winning the award in 2014 and the ThunderStorm System winning the award in 2011.